Results 271 to 280 of about 137,029 (384)

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study

International Journal of Cancer, Volume 157, Issue 3, Page 534-548, 1 August 2025.
What's new? Tumor necrosis factor (TNF) can promote tumor resistance to immune checkpoint inhibitors (ICIs), which are now the standard treatment for advanced melanoma patients. Here, in an advanced melanoma patient cohort, TNF was investigated for a possible predictive relationship with ICI response. Assessments show that after 12 weeks of ICI therapy,
Mathieu Virazels, Amélie Lusque, Stéphanie Brayer, Matthieu Genais, Carine Dufau, Jean Milhès, Thomas Filleron, Cécile Pagès, Vincent Sibaud, Laurent Mortier, Olivier Dereure, Maha Ayyoub, Amandine Fabre, Nathalie Andrieu‐Abadie, Vera Pancaldi, Céline Colacios, Nicolas Meyer, Bruno Ségui, Anne Montfort   +18 more
wiley   +1 more source

MRI imaging of the effects of infliximab in perianal fistulizing Crohn's disease

, 2001
Gert Van Assche, Dirk Vanbeckevoort, Didier Bielen, Georges Coremans, Isolde Aerden, Maja Noman, Séverine Vermeire, Guy Marchal, Freddy Cornillie, Paul Rutgeerts   +9 more
openalex   +1 more source

FRI0060 Successful treatment of active rheumatoid arthritis with chimeric monoclonal antibody to tumour necrosis factor (infliximab): an open study [PDF]

, 2001
K Boki, V. Vassiliou, Garifallia Linardaki, HM Moutsopoulos   +3 more
openalex   +1 more source

Post‐COVID‐19 condition: clinical phenotypes, pathophysiological mechanisms, pathology, and management strategies

The Journal of Pathology, Volume 266, Issue 4-5, Page 369-389, August 2025.
Abstract Post‐COVID‐19 condition (PCC), also known as long COVID, is a complex multiple organ system condition that can develop and persist for months after acute COVID‐19. PCC encompasses a wide range of symptoms, resulting in heterogeneous clinical manifestations. These manifestations likely arise from diverse underlying pathophysiological mechanisms,
Larissa E Vlaming‐van Eijk, Guolu Tang, Arno R Bourgonje, Wilfred F A den Dunnen, Jan‐Luuk Hillebrands, Harry van Goor   +5 more
wiley   +1 more source

IgA Nephropathy Associated With Infliximab Treatment in Patients With Crohn's Disease: Study of IgA1 and IgA2 Expression in Glomeruli. [PDF]

In Vivo
Mima A, Nakamoto T, Matsuki T, Kido S, Saito Y, Morikawa T, Matsumoto K, Gotoda H, Lee S.   +8 more
europepmc   +1 more source

A randomized, double-blind, placebo-controlled trial of intravenous hydrocortisone in reducing human anti-chimeric antibody following infliximab therapy

, 2001
Richard J. Farrell, Mazen Alsahli, Kenneth R. Falchuk, Mark A. Peppercorn, Pierre Michetti   +4 more
openalex   +1 more source

How does infliximab work in rheumatoid arthritis? [PDF]

, 2002
Ravinder N. Maini, Marc Feldmann
openalex   +1 more source

Upadacitinib‐Induced Hemolysis in a Patient With Glucose‐6‐Phosphate Dehydrogenase Deficiency—A Possible Adverse Drug Reaction

Pharmacology Research &Perspectives, Volume 13, Issue 4, August 2025.
ABSTRACT Glucose‐6‐phosphate‐dehydrogenase (G6PD) deficiency is a heterogenous disorder that may lead to severe hemolytic events with the ingestion of fava beans and exposure to certain drugs. We report the first case of a 65‐year‐old male with Crohn's disease who developed a hemolytic crisis leading to hospitalization shortly after commencement of ...
Laura Patanè, Giuseppe Costantino, Marco Muscianisi, Clara De Francesco, Anna Viola, Walter Fries   +5 more
wiley   +1 more source

PAM12: COST-MINIMIZATION ANALYSIS OF THE TREATMENT OF RHEUMATOID ARTHRITIS WITH LEFLUNOMIDE IN COMPARISON WITH THE COMBINATION OF INFLIXIMAB AND METHOTREXATE

, 2001
Carlos Rubio-Terrés, A. Domínguez‐Gil   +1 more
openalex   +1 more source

Psoriasis Skin Clearance, Body Mass Index, and Lifestyle Behaviors

International Journal of Dermatology, EarlyView.
Annika Smith, Melvin Li, Kelvin Truong, Clara Chow, Sarah Zaman   +4 more
wiley   +1 more source